23andMe Holding Co. (MEHCQ)
OTCMKTS
· Delayed Price · Currency is USD
3.965
+0.115 (2.99%)
Jun 4, 2025, 4:00 PM EDT
23andMe Holding Co. Revenue
23andMe Holding Co. had revenue of $60.26M in the quarter ending December 31, 2024, with 34.67% growth. This brings the company's revenue in the last twelve months to $208.78M, down -15.81% year-over-year. In the fiscal year ending March 31, 2024, 23andMe Holding Co. had annual revenue of $219.64M, down -26.66%.
Revenue (ttm)
208.78M
Revenue Growth
-15.81%
P/S Ratio
0.49
Revenue / Employee
365.63K
Employees
582
Market Cap
103.28M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |
23andMe Holding Co. News
- 10 hours ago - 23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher - WSJ
- 12 hours ago - 23andMe seeks new bids after $305 million offer from its co-founder - Reuters
- 2 days ago - 23andMe customers notified of bankruptcy - TechCrunch
- 3 days ago - 23andMe founder aims to restart auction with major corporate backing - Reuters
- 8 days ago - 23andMe to delist from Nasdaq, deregister with SEC - CNBC
- 8 days ago - 23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC - GlobeNewsWire
- 14 days ago - What Regeneron's Purchase Of 23andMe Means For Your Genetic Privacy - Forbes
- 15 days ago - Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains - Seeking Alpha